Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE-2 organ-preservation immunotherapy trial in cutaneous squamous cell carcinoma
2024-516152-17-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical complete remission rate. Planned start Jan 2025; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-516152-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516152-17-00.